Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

2.9K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

226
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
226
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

1.5K
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
1.5K
Pulmonary Embolism I: Introduction01:19

Pulmonary Embolism I: Introduction

30
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
30
Drug Toxicity: Overview01:00

Drug Toxicity: Overview

290
Drug toxicity quantifies the harm a compound causes to an organism, varying by dose and potentially impacting whole systems or specific organs like the liver. Toxic reactions may arise from venomous insect or spider bites, with effects ranging from mild symptoms to severe outcomes such as brain damage or death. Common forms of acute poisoning include ethanol intoxication and overdose of pain or fever medications, with substances like GHB and heroin being particularly lethal at doses close to...
290
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

4.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adverse side-effects of antifibrotic drugs in idiopathic pulmonary fibrosis-clarification of several points.

Journal of thoracic disease·2026
Same author

Expression pattern of circulating long non-coding RNA <i>GAS5</i> as a novel biomarker in non-small cell lung cancer patients.

Archives of medical science : AMS·2026
Same author

Early Functional Impairment in Smokers with CT-Detected Emphysema: Spirometry Provides Complementary Physiological Information in Lung Cancer Screening.

Biomedicines·2026
Same author

Anti-Desmoglein 3 Avidity Correlates Better With Pemphigus Vulgaris Severity Than Anti-Desmoglein 3 Concentration.

International journal of dermatology·2026
Same author

PD-L1 and BAP1 as Prognostic Biomarkers in Malignant Pleural Mesothelioma.

Cells·2026
Same author

Adverse side-effects of antifibrotic drugs and outcome of treatment in idiopathic pulmonary fibrosis.

Journal of thoracic disease·2026

Related Experiment Video

Updated: Apr 23, 2026

Implantation of Total Artificial Heart in Congenital Heart Disease
07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

28.4K

[Amiodarone pulmonary toxicity: case report].

Nada Vasić, Dragica Pesut, Ruza Stević

    Srpski Arhiv Za Celokupno Lekarstvo
    |September 20, 2014
    PubMed
    Summary

    Amiodarone pulmonary toxicity can cause severe respiratory issues, especially in older adults. Promptly discontinuing amiodarone and initiating corticosteroid treatment can lead to significant recovery.

    Area of Science:

    • Cardiology
    • Pulmonology
    • Pharmacology

    Background:

    • Amiodarone, an iodine-rich antiarrhythmic, can accumulate in organs like the lungs.
    • Pulmonary accumulation is influenced by patient age, amiodarone dosage, and treatment duration.

    Observation:

    • A 73-year-old male smoker with COPD and hypertension presented with severe dyspnea and respiratory insufficiency.
    • Chest X-ray showed bilateral pulmonary shadows; amiodarone pulmonary toxicity was diagnosed via elimination and confirmed by bronchoscopy and biopsy.
    • The patient had been treated with amiodarone for six years for atrial fibrillation.

    Findings:

    • Bronchiolitis obliterans organizing pneumonia (BOOP) was pathohistologically confirmed.
    • Treatment involved amiodarone cessation and a course of intravenous and oral methylprednisolone.

    More Related Videos

    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
    05:14

    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

    Published on: May 16, 2020

    4.3K
    Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
    14:24

    Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

    Published on: January 21, 2018

    10.8K

    Related Experiment Videos

    Last Updated: Apr 23, 2026

    Implantation of Total Artificial Heart in Congenital Heart Disease
    07:27

    Implantation of Total Artificial Heart in Congenital Heart Disease

    Published on: July 18, 2014

    28.4K
    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
    05:14

    A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

    Published on: May 16, 2020

    4.3K
    Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
    14:24

    Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model

    Published on: January 21, 2018

    10.8K
  • Significant subjective and objective improvement in respiratory function was observed within weeks, with complete radiographic resolution after eight months.

    • Implications:

    • Amiodarone pulmonary toxicity is a critical consideration in elderly patients presenting with respiratory symptoms and pulmonary changes.
    • Early diagnosis and intervention, including drug cessation and corticosteroid therapy, are crucial for favorable outcomes.
    • This case highlights the importance of considering amiodarone toxicity even with long-term, lower-dose administration.